Experimental oncornavirus vaccines in the cat.
An experimental approach to the immunoprophylatic control of feline oncornavirus-mediated diseases has included induction of antivirus immunity and antibodies to the feline oncornavirus-associated membrane (tumor) antigens. A suitable model for exploring the effectiveness of killed oncornavirus vaccines in the cat has been provided by the use of feline sarcoma virus. Immunization of seven pregnant queens over a 6-week period with ultraviolet light-inactivated Gardner-Arnstein feline sarcoma virus resulted in significant protection among 12 kittens challenged with a tumor-forming Dose 90 at 7 days of age. This immunity was not present in kittens challenged at 35 days of age. Among 12 kittens born of queens immunized during pregnancy with ultraviolet light-inactivated Kawakami-Theilen feline leukemia virus and challenged with the same live virus at 4 days of age, significant protection was noted, ranging from prolongation of survival time to complete protection in 3 kittens. In general, the higher the antibody titer in the mother, the more effective the protection afforded the kittens. Immunization of 43 kittens during their first 5 weeks of life with the same vaccines used in adult cats did not immunize sufficiently to protect against feline sarcoma virus challenge at 5 weeks of age. Neutralizing antibody responses in these kittens were significantly lower than in pregnant queens. That kittens of this age are immunologically responsive was established, since complete protection of 9 kittens to feline sarcoma virus was obtained by immunization with a crude tumor extract inactivated with 5 to 7 megarads of gamma-irradiation. All these kittens developed feline oncornavirus-associated membrane antibodies while 3 developed demonstrable levels of virus-neutralizing antibodies. The results of these studies are believed indicative that killed virus vaccines and tumor vaccines can be effective immunoprophylatic measures in the control of RNA tumor virus oncogenesis in the cat. Developments in this model system should be relevant to any consideration given similar vaccines in humans.
D000367:Age Factors; D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D000951:Antigens, Neoplasm; D002415:Cats; D005260:Female; D005720:Gamma Rays; D008431:Maternal-Fetal Exchange; D009500:Neutralization Tests; D009858:Oncogenic Viruses / Q000276:immunology* / Q000528:radiation effects; D011247:Pregnancy; D011830:Radiation Effects; D012513:Sarcoma, Experimental / Q000382:microbiology / Q000517:prevention & control*; D014466:Ultraviolet Rays; D014611:Vaccination; D014765:Viral Vaccines
D000914:Antibodies, Viral; D000951:Antigens, Neoplasm; D014765:Viral Vaccines